|
|
Blood, 15 May 2004, Vol. 103, No. 10, pp. 3700-3709.
Prepublished online as a Blood First Edition Paper on December 30, 2003; DOI 10.1182/blood-2003-09-3217.
 Previous Article | Table of Contents | Next Article 
GENE THERAPY
Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice
Antonia Follenzi,
Manuela Battaglia,
Angelo Lombardo,
Andrea Annoni,
Maria Grazia Roncarolo, and
Luigi Naldini
From the Laboratory of Gene Transfer and Therapy, Institute for Cancer Research and Treatment (IRCC), University of Torino, Torino, Italy; HSR-Telethon Institute for Gene Therapy, H. San Raffaele Scientific Institute, Milan, Italy; and Vita Salute University, H. San Raffaele Scientific Institute, Milan, Italy.
Stable gene replacement by in vivo administration of lentiviral vectors (LVs) has therapeutic potential for metabolic disorders and other systemic diseases. We studied the expression of intracellular and secreted proteins by LVs in immunocompetent mice. Liver, spleen, and bone marrow cells were efficiently transduced. However, transgene expression, driven by a ubiquitous promoter, was limited by transgene-specific cellular and humoral immune responses, leading to the clearance of transduced cells. After green fluorescent protein (GFP) gene transfer, the liver showed infiltration of CD8+ cytotoxic T cells, and GFP-specific CD8+ T cells were isolated from the spleen. After human factor IX (hF.IX) gene transfer, anti-hF.IX antibodies were induced. These immune responses were not detected in mice injected with heat-inactivated or genome-lacking LVs or in GFP-transgenic mice, indicating that they were specifically triggered by transgene expression in vivo. Intriguingly, selective targeting of LV expression to hepatocytes limited the immune responses to the transgenes. By this approach, high levels of hF.IX, potentially in the therapeutic range, were reached and maintained long term in immunocompetent mice, without inducing antibody formation. These results prompt further studies in relevant animal models to explore the potential of in vivo LV administration for the gene therapy of hemophilias and other liver-based diseases.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Lentiviral vector for hemophilia gene therapy
- Roland W. Herzog
Blood 2004 103: 3609-3610.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
B. D. Brown, A. Cantore, A. Annoni, L. S. Sergi, A. Lombardo, P. Della Valle, A. D'Angelo, and L. Naldini
A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice
Blood,
December 15, 2007;
110(13):
4144 - 4152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Annoni, M. Battaglia, A. Follenzi, A. Lombardo, L. Sergi-Sergi, L. Naldini, and M.-G. Roncarolo
The immune response to lentiviral-delivered transgene is modulated in vivo by transgene-expressing antigen-presenting cells but not by CD4+CD25+ regulatory T cells
Blood,
September 15, 2007;
110(6):
1788 - 1796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Herzog
Interferon limits lentiviral vectors in the liver
Blood,
April 1, 2007;
109(7):
2670 - 2671.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Brown, G. Sitia, A. Annoni, E. Hauben, L. S. Sergi, A. Zingale, M. G. Roncarolo, L. G. Guidotti, and L. Naldini
In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance
Blood,
April 1, 2007;
109(7):
2797 - 2805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. High
Update on Progress and Hurdles in Novel Genetic Therapies for Hemophilia
Hematology,
January 1, 2007;
2007(1):
466 - 472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Dobrzynski, J. C. Fitzgerald, O. Cao, F. Mingozzi, L. Wang, and R. W. Herzog
Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells
PNAS,
March 21, 2006;
103(12):
4592 - 4597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Dobrzynski and R. W. Herzog
Tolerance Induction by Viral In Vivo Gene Transfer
Clin. Med. Res.,
November 1, 2005;
3(4):
234 - 240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kang, L. Xie, D. T. Tran, C. S. Stein, M. Hickey, B. L. Davidson, and P. B. McCray Jr
Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer
Blood,
September 1, 2005;
106(5):
1552 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hanawa, D. A. Persons, and A. W. Nienhuis
Mobilization and Mechanism of Transcription of Integrated Self-Inactivating Lentiviral Vectors
J. Virol.,
July 1, 2005;
79(13):
8410 - 8421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Foote and W. F. Blakemore
Inflammation stimulates remyelination in areas of chronic demyelination
Brain,
March 1, 2005;
128(3):
528 - 539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. VandenDriessche
Liver gene transfer keeps immune system in check
Blood,
August 15, 2004;
104(4):
910 - 911.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Dobrzynski, F. Mingozzi, Y.-L. Liu, E. Bendo, O. Cao, L. Wang, and R. W. Herzog
Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer
Blood,
August 15, 2004;
104(4):
969 - 977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Mitta, C. C. Weber, M. Rimann, and M. Fussenegger
Design and in vivo characterization of self-inactivating human and non-human lentiviral expression vectors engineered for streptogramin-adjustable transgene expression
Nucleic Acids Res.,
July 16, 2004;
32(12):
e106 - e106.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
